Scientific Symposium “Connecting with
Creativity” Draws Prominent Global Scientific Leaders, Nobel Prize
Laureates
Regulatory News:
Ipsen (Euronext: IPN; ADR: IPSEY) today announced the
inauguration of its new R&D center, Ipsen Bioscience, in
Cambridge (MA, USA), a recognized hub in the USA for biomedical
research & innovation. Ipsen's strategic decision to invest in
the Ipsen Bioscience facility in Cambridge is an important element
of the company’s open innovation strategy and its goal of
broadening its partnerships with the American biotechnology,
medical and scientific communities.
To mark the inauguration of the Ipsen Bioscience facility, the
company has organized a scientific symposium with the theme of
"Connecting with Creativity". Several Nobel Prize laureates as well
as other prominent scientists and researchers will participate in
the scientific symposium. His Excellency, Gerard Araud, the
Ambassador of France to the United States, will participate in the
inaugural event ceremonies.
"Cambridge is a major global center for medical research and
development and our presence here will allow us to take full
advantage of the expertise and resources that drive innovation in
Massachusetts," said Marc de Garidel, Chairman and Chief
Executive Officer, Ipsen. “The inauguration of the Ipsen
Bioscience facility today is an opportunity to bring together some
of the world’s leading scientific minds for a scientific symposium
on creativity and innovation. I would like to thank them for
their participation, as well as all our colleagues and
collaborators for their continued support of our scientific
research whose goal is the improvement of human health both in the
United States and globally."
Gérard Araud, the Ambassador of France to the United
States stated: "The domain of health and wellness is one in
which French businesses excel. The USA is the biggest global market
and a major research location in this domain, so it is essential
for French companies to be active leaders in the industry. This is
especially true in the Boston area, which has managed to establish
itself, with its prestigious universities, large hospitals, and
numerous pharmaceutical companies and innovative start-ups, as the
epicenter of new developments in biotechnology. For this reason,
the creation of Ipsen’s new R&D center for the USA here in
Kendall Square, at the heart of the innovation ecosystem of Boston
and Cambridge, constitutes an important sign. This site will permit
Ipsen to benefit from this dynamic environment and also to create
connections between the US location and their state of the art
innovation centers for life science research in France.”
“We are excited to celebrate Ipsen’s expansion and opening of a
new facility in Kendall Square,” said Susan Windham-Bannister,
Ph.D., President & CEO of the Massachusetts Life Sciences
Center. “The life sciences sectors are vital to our state’s
economy, but just as importantly, they enable Massachusetts to make
significant contributions to the quality of life for the global
community. We are so pleased that Ipsen is choosing to expand its
presence in the Massachusetts life sciences community and we look
forward to a continued partnership with the company.”
“We are thrilled to welcome Ipsen’s new R&D center to
Cambridge and happen to believe wholeheartedly in their decision to
locate such a forward-thinking facility in Massachusetts,” said
Robert K. Coughlin, President & CEO of MassBio, the life
sciences trade association. “We know that international companies
looking to grow in the United States will not find a more
concentrated, diverse and collaborative environment for life
sciences anywhere.”
About the scientific symposium
The "Connecting with Creativity" scientific symposium brings
together researchers from very different backgrounds in order to
stimulate debate on creativity, reflecting what science should be:
a system open to the world, searching for investigations rather
than closed assumptions. Creativity is not just a word, but also a
research topic for historical and cognitive sciences. It is also a
reality, as demonstrated by the major discoveries of our time.
Also present will be:
- Steven Shapin (Harvard University)
specialist in the history of scientific revolutions, Antonio
Damasio (director of the Brain and Creativity Institute at the
University of Southern California) and Steven Pinker (professor at
Harvard University), are eminent specialists in cognitive sciences,
and best-selling authors of works of and about pioneering
research.
- The Nobel Prize Laureates Michael
Bishop (University of California, San Francisco), discoverer of
oncogenes and Phillip Sharp (MIT), discoverer of alternative
splicing of eukaryotic cells,
- Robert Langer (MIT) is the David H.
Koch Institute Professor and is the most-cited bioengineer in
history. Dr. Langer’s patents have been licensed or sublicensed to
over 300 pharmaceutical, chemical, biotechnology and medical device
companies.
- David Edwards (Harvard University), who
has excelled as an inventor in numerous domains. He is also
responsible for the creation of "Le Laboratoire" in Paris and in
Cambridge (MA).
- Two other eminent researchers will
chair the sessions:
- Fred Gage, Professor at the Salk
Institute, one of the most renowned scientists in
neurosciences
- Robert Weinberg (MIT), who is
recognized for his research in the area of oncogenes and the
genetic basis of human cancer
A summary of the presentations and the biographies of the
speakers and session chairs is available in the Abstract Book via
www.ipsen.com.
About Ipsen in the United States
Ipsen moved its new R&D center, Ipsen Bioscience, to
Cambridge to be in the number 1 biopharma cluster in the US.
Cambridge is home to renowned academic institutions (Harvard
University, Massachusetts Institute of Technology etc.),
prestigious hospitals (Massachusetts General Hospital, Brigham
& Women Hospital etc.), major players in the biotechnology
sector, start-ups, and several Ipsen partners (e.g. Rhythm, Radius
etc.).
Ipsen Bioscience is developing highly differentiated peptide
therapeutics that address unmet medical needs in endocrinology and
oncology. This work is supported by Ipsen’s peptide and toxin
expertise, notable for the discovery of innovative solutions for
debilitating diseases. Ipsen is one of a few companies to master
the manufacture and control of targeted secretion inhibitors
(TSIs), and are further exploring the potential of peptides to
modulate intracellular protein-protein interactions. The group also
has a clinical research and development team, tasked with the
coordination and carrying out of clinical research in North
America. Ipsen places emphasis on building strong partnerships with
academia and other biotech and pharmaceutical companies to work
together to advance therapeutic opportunities. Although the open
innovation concept is not new for Ipsen, the move to Cambridge
strengthens the opportunity to expand further for the benefit of
patients.
Besides, its state-of-the-art R&D center in the US, Ipsen
also operates in North America. Ipsen Biopharmaceuticals, the North
American operations of Ipsen, has offices located in Basking Ridge,
New Jersey and Toronto, Ontario, Canada. Ipsen Biopharmaceuticals
is focused on the commercialization and the medical and clinical
support of its key products in the areas of oncology, neurology and
endocrinology. The mission of Ipsen Biopharmaceuticals is to
develop and deliver innovative therapies to treat serious illnesses
and, by doing so, to provide hope for patients, families and health
care providers. The company aims to continuously transform itself
to be among the top performing biopharmaceutical companies in the
U.S. and Canada. In 2014, sales of Ipsen in the United States (the
5th country of the Group), amounted to €79.2 million, an increase
of 23.7% at constant currency compared to 2013, based on the strong
volume growth of its core products. In 2014, North American sales
represented 6.2% of total Group sales compared to 5.2% in 2013.
About Ipsen
Ipsen is a global specialty-driven biotechnological group with
total sales exceeding €1.2 billion in 2014. Ipsen sells more than
20 drugs in more than 115 countries, with a direct commercial
presence in 30 countries. Ipsen’s ambition is to become a leader in
specialty healthcare solutions for targeted debilitating diseases.
Its development strategy is supported by 3 franchises: neurology,
endocrinology and urology-oncology. Ipsen’s commitment to oncology
is exemplified through its growing portfolio of key therapies
improving the care of patients suffering from prostate cancer,
bladder cancer or neuroendocrine tumors. Ipsen also has a
significant presence in primary care. Moreover, the Group has an
active policy of partnerships. Ipsen's R&D is focused on its
innovative and differentiated technological platforms, peptides and
toxins, located in the heart of the leading biotechnological and
life sciences hubs (Les Ulis, France; Slough/Oxford, UK; Cambridge,
US). In 2014, R&D expenditure totaled close to €187 million,
representing about 15% of Group sales. The Group has more than
4,500 employees worldwide. Ipsen’s shares are traded on segment A
of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and
eligible to the “Service de Règlement Différé” (“SRD”). The Group
is part of the SBF 120 index. Ipsen has implemented a Sponsored
Level I American Depositary Receipt (ADR) program, which trade on
the over-the-counter market in the United States under the symbol
IPSEY. For more information on Ipsen, visit www.ipsen.com.
Ipsen Forward Looking Statements
The forward-looking statements, objectives and targets contained
herein are based on the Group’s management strategy, current views
and assumptions. Such statements involve known and unknown risks
and uncertainties that may cause actual results, performance or
events to differ materially from those anticipated herein. All of
the above risks could affect the Group’s future ability to achieve
its financial targets, which were set assuming reasonable
macroeconomic conditions based on the information available today.
Use of the words "believes," "anticipates" and "expects" and
similar expressions are intended to identify forward-looking
statements, including the Group’s expectations regarding future
events, including regulatory filings and determinations. Moreover,
the targets described in this document were prepared without taking
into account external growth assumptions and potential future
acquisitions, which may alter these parameters. These objectives
are based on data and assumptions regarded as reasonable by the
Group. These targets depend on conditions or facts likely to happen
in the future, and not exclusively on historical data. Actual
results may depart significantly from these targets given the
occurrence of certain risks and uncertainties, notably the fact
that a promising product in early development phase or clinical
trial may end up never being launched on the market or reaching its
commercial targets, notably for regulatory or competition reasons.
The Group must face or might face competition from generic products
that might translate into a loss of market share. Furthermore, the
Research and Development process involves several stages each of
which involves the substantial risk that the Group may fail to
achieve its objectives and be forced to abandon its efforts with
regards to a product in which it has invested significant sums.
Therefore, the Group cannot be certain that favourable results
obtained during pre-clinical trials will be confirmed subsequently
during clinical trials, or that the results of clinical trials will
be sufficient to demonstrate the safe and effective nature of the
product concerned. There can be no guarantees a product will
receive the necessary regulatory approvals or that the product will
prove to be commercially successful. If underlying assumptions
prove inaccurate or risks or uncertainties materialize, actual
results may differ materially from those set forth in the
forward-looking statements. Other risks and uncertainties include
but are not limited to, general industry conditions and
competition; general economic factors, including interest rate and
currency exchange rate fluctuations; the impact of pharmaceutical
industry regulation and health care legislation; global trends
toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; the Group's ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of the Group’s patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory actions.
The Group also depends on third parties to develop and market some
of its products which could potentially generate substantial
royalties; these partners could behave in such ways which could
cause damage to the Group’s activities and financial results. The
Group cannot be certain that its partners will fulfil their
obligations. It might be unable to obtain any benefit from those
agreements. A default by any of the Group’s partners could generate
lower revenues than expected. Such situations could have a negative
impact on the Group’s business, financial position or performance.
The Group expressly disclaims any obligation or undertaking to
update or revise any forward looking statements, targets or
estimates contained in this press release to reflect any change in
events, conditions, assumptions or circumstances on which any such
statements are based, unless so required by applicable law. The
Group’s business is subject to the risk factors outlined in its
registration documents filed with the French Autorité des Marchés
Financiers.
MediaDidier VéronSenior Vice-President, Public Affairs
and CommunicationTel.: +33 (0)1 58 33 51 16Fax: +33 (0)1 58 33 50
58E-mail: didier.veron@ipsen.comBrigitte Le GuennecMedia and Public
Relations ManagerTel.: +33 (0)1 58 33 51 17Fax: +33 (0)1 58 33 50
58E-mail: brigitte.le.guennec@ipsen.comorFinancial
CommunityStéphane Durant des AulnoisVice President, Investor
RelationsTel.: +33 (0)1 58 33 60 09Fax: +33 (0)1 58 33 50 63E-mail:
stephane.durant.des.aulnois@ipsen.comThomas
Peny-Coblentz, CFAInvestor Relations Deputy DirectorTel.: +33 (0)1
58 33 56 36Fax: +33 (0)1 58 33 50 63E-mail:
thomas.peny-coblentz@ipsen.comorU.S. Media ContactRob
KloppenburgVice President, North America CommunicationsTel:
908-581-2809E-mail: Robert.kloppenburg@ipsen.com
Ipsen (PK) (USOTC:IPSEY)
過去 株価チャート
から 11 2024 まで 12 2024
Ipsen (PK) (USOTC:IPSEY)
過去 株価チャート
から 12 2023 まで 12 2024
